SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-014546
Filing Date
2022-05-16
Accepted
2022-05-16 17:18:25
Documents
15
Period of Report
2022-05-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20220516.htm   iXBRL 8-K 40997
2 EX-1.1 exhibit11-8xk.htm EX-1.1 199730
3 EX-5.1 exhibit51-8xk.htm EX-5.1 14569
7 header1aa.jpg GRAPHIC 107425
  Complete submission text file 0001628280-22-014546.txt   590376

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20220516.xsd EX-101.SCH 1902
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20220516_lab.xml EX-101.LAB 24849
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20220516_pre.xml EX-101.PRE 13046
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20220516_htm.xml XML 11720
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 22930982
SIC: 2834 Pharmaceutical Preparations